Sam Chun Dang Pharm. Co., Ltd
000250
Rang in aandelen
#4334
Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and... Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and produces a wide variety of medications. Its product range features antibiotics, treatments for cardiovascular and respiratory conditions, drugs for the digestive system and ophthalmic use, as well as anti-inflammatory agents. The company was founded on December 29, 1943, and its main operations are based in Hwaseong-si, South Korea.
Aandeelprijs
$152.58
Marktkapitalisatie
$3.57B
Verandering (1 dag)
3.84%
Verandering (1 jaar)
6.02%
Land
KR
Handel Sam Chun Dang Pharm. Co., Ltd (000250)
Categorie
Healthcare
Winst voor Sam Chun Dang Pharm. Co., Ltd (000250)
Winst in Jun 2026 TTM: $22.36M
Volgens de meest recente financiële verslagen van Sam Chun Dang Pharm. Co., Ltd bedraagt de huidige winst van het bedrijf $22.36M. In 2024 behaalde het bedrijf een winst van $7.51M, een stijging ten opzichte van de winst van 2023, die $-3.44M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Sam Chun Dang Pharm. Co., Ltd van 2004 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $22.36M | 158.03% |
| 2025 | $8.66M | 15.41% |
| 2024 | $7.51M | -317.97% |
| 2023 | $-3.44M | -148.73% |
| 2022 | $7.07M | -142.99% |
| 2021 | $-16.44M | -207.66% |
| 2020 | $15.27M | -8.70% |
| 2019 | $16.73M | 28.81% |
| 2018 | $12.99M | -42.52% |
| 2017 | $22.59M | 20.24% |
| 2016 | $18.79M | 5.97% |
| 2015 | $17.73M | -3.02% |
| 2014 | $18.28M | 100.40% |
| 2013 | $9.12M | 61.18% |
| 2012 | $5.66M | -11.95% |
| 2011 | $6.43M | 3.66% |
| 2010 | $6.20M | 25.67% |
| 2009 | $4.94M | -24.16% |
| 2008 | $6.51M | -25.53% |
| 2007 | $8.74M | 151.00% |
| 2006 | $3.48M | -58.00% |
| 2005 | $8.29M | 0.61% |
| 2004 | $8.24M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $1.35B | 5,937.56% |
US
|
|
| $125.33M | 460.58% |
SE
|
|
| $787.12M | 3,420.56% |
FR
|
|
| $739.88M | 3,209.25% |
IT
|
|
| $26.37M | 17.94% |
US
|
